Donald Scott, PhD
- PROFESSOR | Medicine, Endocrinology, Diabetes and Bone Disease
Research Topics:
Cancer, Cell Biology, Cell Cycle, Chromatin, Diabetes, Epigenetics, Gene Expressions, Gene Regulation, Gene Therapy, Growth Factors and Receptors, Hormones, Image Analysis, Imaging, Insulin, Insulin Receptor, Knockout Mice, Liver, Molecular Biology, Nucleus, Obesity, Oncogenes, Protein Kinases, RNA, RNA Splicing & Processing, Transcription Factors, Transcriptional Activation and Repression, Transgenic Mice
Donald Scott, PhD, is a Professor in the Division of Endocrinology, Diabetes and Bone Disease and is a member of the Diabetes, Obesity and Metabolism Institute, and of the Mindich Child Health and Development Institute. Dr. Scott’s group works on the nutritional regulation of cellular phenotype. The Scott Laboratory studies molecular mechanisms that coordinate how nutrients, especially glucose, alter the regulation of genes to change the phenotype of cells. His work focuses on three glucose-sensing transcription factors: ChREBP, Myc and Nrf2. He found that all three factors are necessary for adaptive beta cell proliferation and expansion of beta cell mass in response to a high fat diet. Furthermore, he found that the feed-forward induction of ChREBP-beta, an isoform of ChREBP, drives the adaptive response, but leads to glucose toxicity when expressed at too high a level for too long a time. In addition, he found that activation of Nrf2, a master regulator of antioxidant enzymes, can mitigate the effects of ChREBP-beta-mediated glucose toxicity, but can also stimulate beta cell proliferation even in low concentrations of glucose. Manipulation of these transcription factors may offer unique targets for increasing and preserving beta cell mass in diabetes. His work is funded by the NIH.
Dr. Scott is member of the Graduate Faculty and is affiliated with the Systems Biology of Disease and Therapeutics Multiple Training Area.
Education
AB, University of Missouri
MA, University of Missouri
PhD, Saint Louis University
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Scott did not report having any of the following types of financial relationships with industry during 2021 and/or 2022: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.